TOPIC

/ company

Shanghai Fosun Pharmaceutical

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a unit of one of China’s largest conglomerates Fosun International.

Chairman / President

Wu Yifang

CEO / Managing Director

Wen Deyong

CFO / Finance Director

Gong Ping

Industry

Pharmaceuticals

Website

fosunpharma.com

Headquarters address

Building A, No. 1289 Yishan Road, Shanghai, China

Stock Code

SEHK:2196, SSE:600196

Year founded

1994

Fosun Group

Fosun turns page after property writedowns, shifts focus back to growth

Profit attributable to shareholders rose 160 per cent to 1.72 billion yuan in the six months through June.

27 Aug 2026 - 9:05PM

China-Africa relations

China built megaprojects in Ivory Coast, now its own role is changing

26 Jul 2026 - 5:30PMvideocam

China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

27 May 2026 - 9:00PM

China Conference: Southeast Asia

Fosun Health to build first overseas hospitals in Indonesia amid global push

The Chinese healthcare group is also exploring opportunities to work with local distributors to sell its products in Indonesia.

11 Feb 2026 - 7:11PM

Hu Hang, CEO of Fosun Health Group, speaking at the China Conference: Southeast Asia 2026, on Tuesday. Photo: SCMP

Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

10 Feb 2026 - 4:31PM

Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

6 Feb 2026 - 5:00PM

IPO

China’s Fosun Pharma eyes spin-off Hong Kong IPO of vaccine unit

Fosun Adgenvax (Chengdu) joins an IPO wave that raised more than US$1.5 billion last year for biotech companies.

23 Jan 2026 - 4:16PM

Fosun Adgenvax is expected to remain a subsidiary of Fosun Pharma, which currently owns a 70.08 per cent stake. Photo: Handout

China’s private sector

China’s drug and medical device sector fuels growth with record licensing deals

China’s pharmaceutical industry surges on ageing demand and global expansion, with revenue forecast to top US$2.1 trillion by 2030.

27 Jan 2026 - 3:59PM

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

7 Jan 2026 - 8:30AM

IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

31 Dec 2025 - 2:26PM

Insilico is training and testing an AI-powered drug-discovery tool to enable faster, cheaper and more successful drug discovery. Photo: Handout

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

20 Dec 2025 - 8:57AM

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

16 Dec 2025 - 3:47PM

Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

10 Dec 2025 - 4:39PM

China’s private sector

Fosun brings UK particle therapy to mainland China in advanced cancer care push

The US Food and Drug Administration-approved Marie system promises human-centred care, advanced technology and lower costs.

7 Nov 2025 - 7:30AM

Fosun Pharmaceutical says the Marie system could reduce total treatment costs by 50 per cent compared with existing therapies. Photo: Daniel Ren

Greater Bay Area

Unmet healthcare demand in Asia presents Chinese hospitals with opportunities

Fosun Health is targeting medical tourists from South Asia, Southeast Asia and the Middle East, CEO Frank Hu Hang says.

21 Oct 2025 - 2:53PM

Frank Hu Hang, chairman and CEO of Fosun Health, plans to expand healthcare services to others parts of Asia. Photo: Peggy Sito

China-Africa relations

China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects

Move to manufacture insulin locally is set against forecast of nearly 55 million Type 2 diabetes cases in sub-Saharan Africa by 2045.

11 Oct 2025 - 2:00PMvideocam

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

4 Oct 2025 - 10:56AM

Fosun Group

Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms about selling them the rights to an experimental cancer drug.

16 Sep 2025 - 4:30PM

Fosun International’s Guo Guangchang. Photo: Thomas Yau

Robotics

Hong Kong surgical robot start-up Cornerstone takes aim at da Vinci

Company aims to raise US$70 million to develop its systems, which it claims rival the market-leading da Vinci units at lower cost.

26 May 2025 - 3:46PM

Health in China

Chinese pharmaceutical companies look abroad for growth markets

Shanghai Henlius struck a deal in Saudi Arabia while XtalPi signed a partnership with Sinar Mas Multiartha in Indonesia.

11 Nov 2024 - 7:01PM

Hong Kong stock market

Shanghai biotech firm’s shares soar after Fosun’s US$690 million buyout offer

Henlius joins a wave of companies that have left Hong Kong’s stock market this year, either through privatisation or voluntary delisting having found themselves undervalued.

25 Jun 2024 - 5:20PMvideocam

Phosun Pharma will pay a premium of 36.7 per cent over Monday’s closing price of HK$18 for Henlius. Photo: Reuters

Shenzhen

Chinese drugs giant, Shenzhen team up to invest in city’s biomedical start-ups

Fosun Pharma will team up with Shenzhen’s government to raise a 5-billion yuan (US$700 million) healthcare fund to invest in start-ups and innovations in cellular biology, genetics and other fields related to biomedicine.

14 Mar 2024 - 7:00PMvideocam

Medicine

Fosun Pharma to deliver China-made surgical robots in key medical milestone

The Fosun Group is looking to make another major leap in the healthcare industry as it prepares to deliver locally-made surgical robots to hospitals.

12 Nov 2023 - 4:14PMvideocam

China's border reopening

Shanghai Fosun sees mainland demand for Omicron-focused BioNTech shot in Hong Kong

Long queues of mainland Chinese nationals looking to receive the mRNA vaccine have been seen outside Hong Kong clinics following a re-opening of the border.

12 Jan 2023 - 7:48AM

Medicine

Fosun mulls sale of Indian drug maker Gland valued at US$3.6 billion

A sale of Hyderabad-based Gland, which specialises in injectable drugs such as antibiotics, oncology and cardiology treatments, will help Fosun raise cash and shore up its balance sheet.

29 Nov 2022 - 3:02PM

Fosun Pharma is in talks with prospective buyers to sell its stake in India’s Gland Pharma. Photo: Reuters

Banking & finance

Fosun sells assets amid credit downgrades, liquidity pressure

Fosun International has sold some of its peripheral assets to raise almost US$100 million in cash in recent weeks, as credit rating cuts heighten concerns about the conglomerate’s financial strength.

20 Sep 2022 - 6:40PM

Coronavirus China

Home-grown vaccine back on the agenda, China energises ‘scientific’ strategy

Remarks by Vice-Premier Liu He suggest vaccine development remains on the agenda for China, with clinical trials of a home-grown Omicron jab having started in Zhejiang.

1 Jun 2022 - 6:30AMvideocam

Fosun Group

Fosun sees profit rise, set to make generic Pfizer, Merck Covid-19 pills

Shanghai Fosun Pharmaceutical Group is looking into which of its existing plants can be used to manufacture generic versions of Pfizer’s nirmatrelvir, which is sold under the Paxlovid brand name, and Merck’s molnupiravir.

24 Mar 2022 - 6:20PMvideocam

Help preserve 120 years of quality journalism.

SUPPORT NOW